Stifel analyst Rick Wise maintains $GE HealthCare Technologies (GEHC.US)$ with a buy rating, and adjusts the target price from $100 to $102.
According to TipRanks data, the analyst has a success rate of 58.6% and a total average return of 4.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $GE HealthCare Technologies (GEHC.US)$'s main analysts recently are as follows:
GE HealthCare shares have ascended by 20% since the beginning of the year and are approaching record levels. They are currently valued at a 5% premium compared to their close peer, Siemens Healthineers, which contrasts with their usual 18-month average discount of 15%. This valuation seems challenging to justify in light of GE HealthCare's diminished growth prospects, suggesting that investor expectations might surpass even those of sell-side consensus. It is anticipated that GE's growth in the near to medium term may not meet expectations.
GE HealthCare experienced positive developments with the FDA's approval of Flurpiridaz, a pioneering myocardial perfusion imaging PET radiopharmaceutical that is produced as an 'individual dose' beforehand, in contrast to the current requirement for on-site manufacturing. Analysts suggest that due to its notable clinical advantages over other MPI radiopharmaceuticals, Flurpiridaz is expected to be rapidly adopted by existing cardiac PET centers in the U.S., potentially broadening the access to cardiac PET significantly.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.